Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $566M | $612M | $652M | $698M | $715M | $587M | $684M | $673M | $688M | $701M |
| Revenue growth | — | 8.0% | 6.7% | 6.9% | 2.5% | -17.9% | 16.5% | -1.6% | 2.2% | 1.9% |
| Gross profit | $297M | $337M | $391M | $402M | $371M | $299M | $394M | $380M | $381M | $354M |
| Gross margin | 52.5% | 55.1% | 59.9% | 57.7% | 51.9% | 51.0% | 57.6% | 56.4% | 55.4% | 50.5% |
| Operating income | -$107M | -$43.1M | $500K | -$55.7M | -$48.5M | -$39.0M | $35.5M | $4.20M | -$396M | -$61.6M |
| Operating margin | -18.9% | -7.0% | 0.1% | -8.0% | -6.8% | -6.6% | 5.2% | 0.6% | -57.6% | -8.8% |
| Net income | $39.8M | $79.3M | $57.5M | -$45.9M | -$29.0M | $6.30M | $50.5M | -$61.8M | -$392M | -$72.9M |
| Net margin | 7.0% | 13.0% | 8.8% | -6.6% | -4.1% | 1.1% | 7.4% | -9.2% | -57.0% | -10.4% |
| EPS (diluted) | $0.85 | $1.69 | $1.22 | -$0.96 | -$0.61 | $0.13 | $1.07 | -$1.32 | -$8.53 | -$1.57 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $189M | $144M | -$146M | -$74.5M | -$2.50M | $87.3M | $90.9M | $32.4M | $101M | $74.7M |
| Capital expenditures | $29.1M | $43.2M | $49.1M | $50.6M | $20.2M | $21.0M | $19.3M | $17.8M | $17.8M | $31.6M |
| Free cash flow | $160M | $101M | -$195M | -$125M | -$22.7M | $66.3M | $71.6M | $14.6M | $82.9M | $43.1M |
| Share buybacks | $900K | $2.50M | $900K | $3.60M | $900K | $11.5M | $45.5M | $19.1M | $12.8M | $3.30M |
| Dividends paid | — | — | $0.00 | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $114M | $220M | $385M | $205M | $112M | $119M | $128M | $87.7M | $108M | $89.8M |
| Total assets | $2.07B | $2.20B | $1.83B | $1.80B | $1.67B | $1.60B | $1.79B | $1.69B | $1.15B | $1.07B |
| Total liabilities | $969M | $981M | $536M | $534M | $416M | $333M | $496M | $456M | $326M | $296M |
| Long-term debt | $589M | $589M | $250M | $248M | $180M | $130M | $226M | $159M | $125M | $90.3M |
| Shareholders' equity | $1.10B | $1.22B | $1.30B | $1.27B | $1.26B | $1.27B | $1.29B | $1.24B | $829M | $778M |
| Retained earnings | -$379M | -$300M | -$242M | -$288M | -$316M | -$304M | -$253M | -$315M | -$707M | -$780M |
| Shares (wtd avg diluted) | 46.6M | 46.8M | 47.2M | 47.6M | 47.8M | 48.6M | 47.3M | 46.6M | 46.0M | 46.3M |
Every figure is extracted from AVANOS MEDICAL, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.